Results 71 to 80 of about 1,217,759 (290)

Immune persistence and response to booster dose of Vi-DT vaccine at 27.5 months post-first dose

npj Vaccines, 2022
Vaccination with typhoid conjugate vaccines (TCV) is a major part of typhoid prevention. However, little is known about long-term immune persistence following vaccination with TCVs.
Maria Rosario Capeding, Birkneh Tilahun Tadesse, Arijit Sil, Edison Alberto, Deok Ryun Kim, Eun Lyeong Park, Ju Yeon Park, Jae Seung Yang, Jagadeesh Reddy Eluru, Sue-Kyoung Jo, Hun Kim, Seon-Young Yang, Ji Hwa Ryu, Hokeun Park, Jong Hoon Shin, Yoonyeong Lee, Jerome H. Kim, Zenaida Reynoso Mojares, T. Anh Wartel, Sushant Sahastrabuddhe   +19 more
doaj   +1 more source

SG-APSIC1158: COVID-19 vaccine booster hesitancy among healthcare workers: A retrospective observational study in Singapore

Antimicrobial Stewardship & Healthcare Epidemiology, 2023
Objectives: COVID-19 booster uptake has remained poor among healthcare workers (HCWs) despite evidence of improved immunity against the SARS-COV-2 δ (delta) and ο (omicron) variants. Although most studies have used a questionnaire to assess hesitancy, we
Sky Wei Chee Koh, Hwei Ming Tan, Wayne Han Lee, Jancy Mathews, Doris Young   +4 more
doaj   +1 more source

Pediatric Idiopathic Multicentric Castleman Disease Is Often Severe But Responsive to Siltuximab

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Idiopathic multicentric Castleman disease (iMCD) is a potentially fatal immunologic disorder marked by widespread lymphadenopathy and inflammation. Siltuximab, an interleukin‐6 (IL‐6) inhibitor, is the only FDA‐approved treatment for adult patients with iMCD.
Bridget Austin, Sheila K. Pierson, Kelley C. Dacus, Mateo Sarmiento Bustamante, Saishravan Shyamsundar, Larissa Borys, Kayla McHugh, Abiola Irvine, Yoojin Jo, Adam Bagg, Mary Jo Lechowicz, Daisy Alapat, Amy Chadburn, Megan S. Lim, Gordan Srkalovic, Frits van Rhee, David C. Fajgenbaum, Joshua D. Brandstadter   +17 more
wiley   +1 more source

The Persistence of Antibodies in ESRD Patients 12 Months after the BNT162b2 Vaccine Booster Dose. [PDF]

End-stage renal disease (ESRD) patients undergoing haemodialysis have been reported to have impaired humoral response after coronavirus disease 2019 vaccination. However, most studies focus on one antibody profile or one-time point only.
Abdullah Shamsir, Abd Mokti, Mohammad Hanif, Hashim, Awla, Mohd Azraai, Ahmad Mahfuz, Gazali, Hajar Fauzan, Ahmad, Ummu Afeera, Zainulabid   +5 more
core   +7 more sources

Venetoclax‐Based Therapy as a Bridge to Hematopoietic Stem Cell Transplantation in Relapsed or Refractory Pediatric Acute Leukemia

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Relapsed and/or refractory (R/R) pediatric acute leukemia carries a dismal prognosis, largely driven by chemoresistance to conventional salvage therapy. The BH3‐mimetic venetoclax, combined with chemotherapy or hypomethylating agents, has demonstrated efficacy in small clinical trials.
Katherine S. Colman, Deborah Meyran, Vajiranee Malalasekera, Heather Weerdenburg, Janine Campbell, Rachel Conyers, Stacie Wang, Hannah Walker, Seong Lin Khaw, Diane Hanna   +9 more
wiley   +1 more source

A survey on Malaysian\u27s acceptance and perceptions towards COVID-19 booster dose

, 2023
Progressive reopening of the economy and declaration of COVID-19 as endemic has relaxed social distancing and mask-wearing necessities in Malaysia. The Ministry of Health of Malaysia reported vaccination rate had reached 86.1% for the first dose and 84.3%
Rajakumar, Sutha, Alshawsh, Mohammed Abdullah, Huri, Hasniza Zaman, Rajakumar, Suresh, Shamsuddin, Noorasyikin   +4 more
core   +1 more source

Immunogenicity and safety of an investigational quadrivalent meningococcal conjugate vaccine administered as a booster dose in children vaccinated against meningococcal disease 3 years earlier as toddlers: A Phase III, open-label, multi-center study

Human Vaccines & Immunotherapeutics, 2022
Booster doses of meningococcal conjugate vaccines induce long-term protection against invasive meningococcal disease. We evaluated the immunogenicity and safety of a booster dose of MenACYW-TT in pre-school children who were primed 3 years earlier with ...
Franco M. Piazza, Miia Virta, Marita Paassilta, Benita Ukkonen, Anitta Ahonen, Alejandra Esteves-Jaramillo, Aino Forsten, Ilkka Seppa, Jian Ding, David Neveu, Emilia Jordanov, Mandeep S. Dhingra   +11 more
doaj   +1 more source

Biphasic Clinical Course of Pediatric Cytomegalovirus‐Associated Immune Thrombocytopenia: Early Poor Treatment Response but Favorable Long‐Term Outcomes

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Cytomegalovirus (CMV) is a recognized trigger of immune thrombocytopenia (ITP); however, its incidence and impact on disease course in children remain controversial. Therefore, we aimed to characterize the clinical course of pediatric patients with CMV‐associated ITP.
Oded Gilad, Ohad Atia, Osama Tanous, Dafna Brik Simon, Michal Dvori, Miriam Cohen, Tracie A. Goldberg, Efraim Bilavsky, Joanne Yacobovich, Orna Steinberg‐Shemer   +9 more
wiley   +1 more source

Experience With Performing Rheocarna Therapy via the Single‐Needle Method for Treatment of Chronic Limb‐Threatening Ischemia

Therapeutic Apheresis and Dialysis, EarlyView.
ABSTRACT Introduction This study investigated the safety and efficacy of single‐needle Rheocarna therapy for chronic limb‐threatening ischemia (CLTI) with wounds. Methods Six patients with CLTI involving ulcers unresponsive to revascularization underwent single‐needle Rheocarna treatment.
Yasutaka Yamauchi, Rie Tanaka, Reona Kawahira, Shingo Nabeta, Kouhei Naoi, Kazuhito Kitajima, Akira Wada, Tomonari Takagi, Norihiko Ohura, Akira Miyamoto   +9 more
wiley   +1 more source

Inactivated hepatitis A vaccine booster given >/=24 months after the primary dose.

, 2000
We investigated what happens with the immune response when people come back for their booster dose of inactivated hepatitis A vaccine later than the recommended time of 6-12 months after the primary dose.
Tremblay, S., Landry, P., Darioli, R., Genton, B.   +3 more
core   +1 more source